Sunshine Nuohe announced that Nuohe Shengtai, a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for the STC009 injection project under development was approved. This injection is a Class 1 innovative drug. The intended application is secondary hyperparathyroidism. Non-clinical studies have shown that it has a good effect in lowering serum PTH, greatly reduces the risk of hypocalcaemia, and is well tolerated. The drug development cycle is long and involves many steps, and is easily affected by uncertainties. Investors are reminded to make careful decisions and be aware of risks.

Sunshine Nuohe announced that Nuohe Shengtai, a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for the STC009 injection project under development was approved. This injection is a Class 1 innovative drug. The intended application is secondary hyperparathyroidism. Non-clinical studies have shown that it has a good effect in lowering serum PTH, greatly reduces the risk of hypocalcaemia, and is well tolerated. The drug development cycle is long and involves many steps, and is easily affected by uncertainties. Investors are reminded to make careful decisions and be aware of risks.